"Dear colleagues, welcome back to the Onco Alert newsletter, 9 years of follow-up confirmant. Nivolumab plus ipilimumab remains a standard of care in advanced kidney cancer with durable survival benefits, holding steady over synitinib. In lung cancer, we're unpacking why TP53 gain-of-function mutations are driving early resistance to ozomyrtinib and what that means for your next-line strategy. In breast cancer, new phase 2 data shows pairing radiation with immunotherapy may crack open cold PD-L1- tumors. And don't miss our deep dive into hemoguide, an AI tumor board assistant hitting over 80% concordance with human experts, with a hallucination rate of near zero. Plus updates across GI, GU, gynecological oncology, all the studies, all the take-away, one newsletter. Read it on OncoAlert."